Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer

BACKGROUND: Triple-negative breast cancer (TNBC) represents an aggressive breast cancer subtype with historically poor overall outcomes, due primarily to a lack of effective targeted agents. Chemotherapy has been the primary treatment approach, although immune checkpoint inhibitors (ICIs) are curren...

Descripción completa

Detalles Bibliográficos
Autores principales: Simmons, Christine E., Brezden-Masley, Christine, McCarthy, Joy, McLeod, Deanna, Joy, Anil Abraham
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
TNBC in 2019: Promising Signals for the Treatment of a Formidable Disease
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7517981/
https://www.ncbi.nlm.nih.gov/pubmed/33014143
http://dx.doi.org/10.1177/1758835920909091

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7517981/
https://www.ncbi.nlm.nih.gov/pubmed/33014143
http://dx.doi.org/10.1177/1758835920909091

Ejemplares similares